کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy)

Shabnam Movassaghi 1, Zahra Nadia Sharifi 1, Farzaneh Mohammadzadeh 2, Mansooreh Soleimani 3,4 *

1 Department of Anatomy, Islamic Azad University Tehran Medical Branch, Tehran, Iran
2 Department of Anatomy, Tehran University of Medical Sciences, Tehran, Iran
3 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
4 Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran

Keywords: Apoptosis, Fibrosis, Liver, MDMA, Pentoxifylline

ABSTRACT

Objective(s): 3,4-Methylenedioxymethamphetamine (MDMA) is one of the most popular drugs of abuse in the world with hallucinogenic properties that has been shown to induce apoptosis in liver cells. The present study aimed to investigate the effects of pentoxifylline (PTX) on liver damage induced by acute administration of MDMA in Wistar rat.

Materials and Methods: Animals were administered with saline or MDMA (7.5 mg/kg, IP) 3 times with 2 hr intervals. PTX (200 mg kg, IP), was administered simultaneously with last injection of MDMA in experimental group.

Results: The concomitant administration of pentoxifylline and MDMA decreased liver injury including apoptosis, fibrosis and hepatocytes damages.

Conclusion: Our results showed for the first time that PTX treatment diminishes the extent of apoptosis and fibrosis caused by MDMA in rat liver.

Introduction

3,4-Methylenedioxymethamphetamine (MDMA or ecstasy), is a psychoactive recreational hallucinogenic substance and a major worldwide drug of abuse (1).

The liver may be considered as the most important organ in drug toxicity for two reasons: 1- it is functionally interposed between the site of absorption and the systemic circulation and is a major site of metabolism and elimination of foreign substances; 2- these features also render liver a preferred target for drug toxicity. Drug-induced liver injury (DILI) therefore poses a major clinical problem (2).

Acute exposure to MDMA alone or in combination with other substances, can damage several organs such as the heart, liver, kidney, and brain and can be fatal. The life threatening clinical manifestations of MDMA toxicity also include acute hepatic damage (3-5). Despite the well-established toxicities associated with its abuse, MDMA is the second most common cause of liver injury in people under the age of 25 (1) and has been shown to produce cell necrosis and fibrosis in the liver (6).

Although many reports have demonstrated MDMA-induced liver damage (7-9), the underlying mechanism is poorly understood. One proposed mechanism is that the reactive metabolites of MDMA are responsible for hepatotoxicity. Increased production of ROS and/or toxic oxidation products with GSH depletion may be responsible for liver damage (10-12).

Increased oxidative stress causes organ damage and apoptosis. Mitochondria, fat and anti-oxidant defense are known to be a major target of increased oxidative/nitrosative stress upon exposure to toxic compounds and/or in pathological conditions (13, 14). It is possible that MDMA and/or its reactive metabolites inhibit the mitochondrial function by directly interacting with mitochondrial proteins (15). In addition, MDMA and metabolites can indirectly cause mitochondrial dysfunction through increased oxidative/nitrosative stress (16, 17).

*Corresponding author: Mansooreh Soleimani. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Tel: 09194043522; email: mansourehsoleimani@gmail.com
Pentoxifylline Protects Rat Liver Against Ecstasy

Movassaghi et al

Iran J Basic Med Sci, Vol. 16, No. 8, Aug 2013

Many liver injuries such as jaundice, hepatomegaly, centrilobular necrosis, hepatitis and fibrosis may be caused by MDMA and it is clarified that this drug can induce hepatocellular damage (9).

Pentoxifylline (PTX), a methylxanthine derivative and a nonspecific type 4 phosphodiesterase inhibitor, is clinically used in the treatment of lower extremity claudication. The mechanisms underlying its beneficial effects seem to be related to alterations in cellular functions and to the improvement of microcirculatory perfusion in both peripheral and cerebral vascular beds (18-19).

Serum level of cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and IL-8 are elevated in acute alcoholic hepatitis (20). Recently, PTX, with combined anti-inflammatory (TNF-α inhibition) and antifibrogenic properties, has been found to be useful in patients with acute alcoholic hepatitis (21, 22).

The objectives of the present work were to investigate the possible protective effects of pentoxifylline on a hepatotoxicity due to high dose of MDMA.

Materials and Methods

Animals and chemicals

Adult male Wistar rats (12-13 weeks-old) weighing (250-300 g) from Pharmacology department of Tehran University of Medical Sciences were used in all experiments. The rats were housed under a 12 hr light/dark cycle. Animals were allowed free access to food and water.

All chemicals were purchased from Sigma except PTX powder that was gifted kindly by the Amin Pharmaceutical Co (Esfehan-Iran) and pure MDMA was gifted by Dr Foroumadi, Faculty of Pharmacy and Pharmacetical Sciences Research Center, Tehran University of Medical Sciences.

Experimental groups and drug

Animals (n=24) were divided randomly into 4 groups as described below:

1- Control group: Animals were euthenized after 2 weeks.

2- Ecstasy group: 7.5 mg/kg MDMA was injected intraperitoneally (IP) three times every 2 hr.

3- Experimental group: 7.5 mg/kg MDMA was injected intraperitoneally (IP) three times every 2 hours. After the last injection of MDMA, 200 mg/kg PTX was injected IP.

4- Vehicle group: 7.5 mg/kg MDMA was injected intraperitoneally (IP) three times every 2 hr. After the last injection of MDMA, normal saline was injected IP.

Animals were sacrificed after 2 weeks. Livers were removed for histological assessment (H&E and trichrom-Masson) and TUNEL technique for apoptosis.

Histopathology

After fixation in 4% paraformaldehyde, samples were embedded in paraffin. Sections of 5 micron in thickness were subjected to haematoxylin and eosin and Masson's trichrome staining and 3 µm thickness for TUNEL technique prior to examinations. Hepatic morphology was assessed by light microscopy.

A total of five sections for each liver tissue sample were observed under light microscope.

In H&E staining, damaged hepatocytes graded as 1= normal 2= mild damage (swollen and pale cytoplasm) 3= moderate damage (vacualated cytoplasm) and 4= severe damage (pyknotic nucleus and eosinophil cytoplasm) (Figure 1).

TUNEL staining

For TUNEL staining, paraffin blocks were cut into 3 µm thickness coronal sections. To detect apoptotic cells, TUNEL staining was performed using an In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) according to the manufacturer’s protocol.
null
Discussion

MDMA, a methamphetamine derivative known as ‘ecstasy’, and other drugs with similar effects are widespread in the world. Ecstasy can be incriminated in causing the liver damage. Many studies showed that the hepatotoxicity induced by MDMA is a consequence of the metabolism of MDMA (26).

Liver fibrosis and its end-stage disease, cirrhosis, are outcomes of many chronic liver diseases, such as viral hepatitis and of alcohol consumption and drug abuse (27).

It has been reported that liver toxicity is one of the consequences of ecstasy abuse. Various factors may play role in ecstasy-induced hepatotoxicity, namely its metabolism, the increased efflux of neurotransmitters, the oxidation of biogenic amines, and hyperthermia (7). MDMA undergoes extensive hepatic metabolism that produce reactive metabolites which form adducts with intracellular nucleophilic sites. Consumption of MDMA involves the production of TNF-α and promote multiple mechanisms to initiate apoptosis in hepatocytes (7).

Many studies have indicated that each of the amphetamine derivatives have direct effects including the induction of apoptosis by phosphorylation (inactivation) of Bcl-2 in MDMA-exposed tissue (28, 29).

The mechanism of hepatic injury induced by MDMA administration is unclear but a spectrum of severity seems to exist as assessed with histological changes varying from a mild to moderate lobular hepatitis to features of massive hepatic parenchymal collapse with areas of nodular regeneration. (30)

Therapeutic effect of pentoxifylline on hepatic lesions induced by ecstasy has not been studied but some studies have shown that pentoxifylline is used for the treatment of liver lesions caused by alcohol (31, 32), liver lesions after surgery (33, 34), bacterial-induced hepatopathy (35, 36) and many other types of liver damage.

The beneficial effects are believed to occur through various mechanisms such as inhibition of phosphodiesterases, increased cAMP levels and downregulation of TNF-α, IL-1, IL-6, transforming growth factor-beta (TGF-β), interferon-gamma (IFN-γ), stellate cell activation and procollagen-I mRNA expression (23).

Ecstasy-induced apoptosis plays a major role in liver injury and is often seen with inflammation and fibrosis (37). Pentoxifylline can inhibit TNFα by reducing the transcription of its gene and also can reduce inflammation by affecting cytokine/chemokine pathway (38).

In this study, we investigated the effect of pentoxifylline on liver lesions in Wistar rats. For the first time in 1991, the therapeutic effect of pentoxifylline on hepatorenal syndrome was studied (39). Later, the beneficial effect of this drug was shown on alcoholic hepatitis by some researchers (40). PTX has been proposed as an effective strategy in treating alcoholic hepatitis, and even in reduction in secondary complications such as hepatic encephalopathy syndrome and hepatorenal syndromes (31, 41). Anti-fibrotic effect of pentoxifylline due to inhibition of profibrogenic cytokine and procollagen I expression is shown by some studies (42). Pentoxifylline can decrease the AST (Aspartate aminotransferase) and ALT (Alanin aminotransferase) levels and its anti-TNF-α effect also improves symptoms of liver tissue in patients with NALFD (Non-alcoholic steatohepatitis)/NASH Non-alcoholic fatty liver disease (43).

The results of this study showed decrease in apoptosis and consequently anti-fibrotic properties of pentoxifylline after ecstasy administration.

Conclusion

The present study indicates that the number of apoptotic bodies have been decreased effectively after treatment with 200 mg/kg dose of pentoxifylline. It has been concluded that pentoxifylline can reduce ecstasy-induced hepatic lesions and fibroses in Wistar rats.

Acknowledgment

This work was supported by Cellular and molecular research center, Tehran University of Medical Sciences. Authors would like to thank Amin Pharmaceutical Co (Esfahan-Iran) for the gift of pentoxifylline, Dr Foroumady for kindly gift of MDMA and Research Center of Islamic Azad University, Tehran Medical Branch, Tehran, Iran.

References

1. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229:986-988.
2. Russmann S, Kullak-Ublick GA, Grattaglione I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16:3041-3053.
3. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751–1752.
4. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159:2221–2224.
5. Kuypers KP, Samyn N, Ramaekers JG. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function. Psychopharmacology 2006; 187:467–475.
6. Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxyxymethamphetamine (“ecstasy“) usage. J Clin Gastroenterol 1995; 20:244-247.
7. Cerretani D, Bello S, Cantatore S, Fiaschi AI, Montefrancoes G, Neri M, Pomara C. Acute administration of 3,4-methylenedioxymethamphetamine (MDMA) induces oxidative stress, liperoxidation and TNFα-mediated apoptosis in rat liver. Pharmacol Res 2011; 64:517-527.

8. Turillazzi E, Riezzo I, Neri M, Bello S, Fineschi V. MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. Curr Pharm Biotechnol 2010; 11:500-509.

9. Carvalho M, Pontes H, Remião F, Bastos ML, Carvalho F. Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol 2010; 11:476-495.

10. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Carvalho F, et al. The toxicity of N-methyl-alpha-methylamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004; 200:193–203.

11. Boobis AR, Trosh MA, Penning TM, Dryhurst G, Mons T. Role of quinones in toxicology. Chem Res Toxicol 2000; 13:135–160.

12. Montiel IC, Ansorena E, Lopez-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ, Cenarruzabeitia E, et al. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxy methamphetamine ("Ecstasy") on hepatic stellate cells. Biochem Pharmacol 2004; 67:1025–1033.

13. Bindoli A, Righelato MP, Deeble DJ, Bichello M, Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chem Res Toxicol 2006; 19:1294–1304.

14. Fisher AA, Labenski MT, Malladi S, Golkhaile V, Bowen ME, Milleron RS, et al. Quinone electrophiles selectively adduct "electrophile binding motifs" within cytochrome c. Biochemistry 2007; 46:11090–11100.

15. Moon KH, Hood BL, Kim BJ, Hardwick JP, Conrads TP, Veenstra TD, et al. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology 2006; 44:1218–1230.

16. Moon KH, Abdelmegeed MA, Song BJ. Inactivation of cytosolic aldehyde dehydrogenase via S-nitro-sylation in ethanol-exposed rat liver. FEBS Lett 2007; 581:3967–3972.

17. Seifig D. Pentoxifylline: its influence on interaction of cancer cells with the vessel wall. Atherosclerosis 1997; 131:27–28.

18. Windmeier G, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29:81–196.

19. McIlroy CJ, Song Z, Barve SS, Hill DB, Deacius I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G497-502.

21. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637–1648.

22. Louvet A, Diaz E, Dharancy S, Cooevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008; 48:465–470.

23. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 7:15:1613–1619.

24. Wu J, Liu J, Waaikles MP, Cheng ML, Li Li, Li CX, et al. High dietary fat exacerbates arsenic-induced liver fibrosis in mice. Exp Biol Med (Maywood) 2008; 233:377–384.

25. Moragas AH, Allende M, Sans: Characteristics of perinuclear collagen aggregation in liver cirrhosis: Computer-assisted quantitative analysis. Anal Quant Cytol Histol 1998; 20:169–177.

26. Upeti VV, Moon KH, Yu LR, Lee JL, Eddington ND, Ye X, Veenstra TD, Song BJ. Increased oxidative-modifications of cytosolic proteins in 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-exposed rat liver. Proteomics 2011; 11:20.02-211

27. Elsharkawy AW, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005;10:927–939.

28. Brichese L, Cazettes G, Valette A. JNK is associated with Bcl-2 and PP1 in mitochondria: padicaxel induces its activation and its association with the phosphorylated form of Bcl-2. Cell Cycle 2004; 3:1312–1319.

29. De Chiara G, Marcocci ME, Torcia M, Lucibello M, Labropoulou-Karatza C. Pentoxifylline-a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 2009; 15:3194–3195.

30. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38:454–458.

31. Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C. Pentoxifylline-a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 2009; 15:3194–3195.

32. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15:1613-1619.

33. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78:1205–1211.

34. Stockschälder M, Kalhs P, Peters S, Zeller W, Krüger W, Kabisch H, Lachner K, Zander A. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12:357-362.

35. van Miert AS, van Duijn CT, Wensing T. Effects of pentoxifylline and polymyxin B on the acute-phase-
response to Escherichia coli endotoxin in dwarf goats. J Vet Pharmacol Ther 1997; 20:61-68.
36. Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H, Lilly CM, O’Hanley PT, Rafin TA. The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 1989; 140:974-980.
37. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a dear and present danger. Physiol Rev 2010; 90:1165-1194.
38. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004; 19:1106-1115.
39. McHutchison JG, Runyon BA, Draguesku JO, Cominelli F, Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14:96A
40. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637-1648.
41. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician’s guide to diagnosis and therapy. World J Gastroenterol 2010 21; 16:4905-4912.
42. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50:241-247.
43. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10:49.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله